Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 3/20 | 0.53 |
| ▸ | GALR1 | P47211 | 2/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 10/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452881 | 0.87 | IDH2 (0.53) | PIK3CAABL1HPGDBCRMAPK1 | |
| SCHEMBL13127052 | 0.83 | PIK3CA (0.55) | GALR2GALR1PIK3CAHPGDKDM4E | |
| SCHEMBL3450867 | 0.82 | GALR2 (0.51) | GALR2ABL1KCNH2MCHR1BCR | |
| SCHEMBL3452010 | 0.81 | IDH2 (0.67) | PIK3CAHPGDMAPTIDH2 | |
| SCHEMBL3452006 | 0.81 | PIK3CA (0.53) | GALR2GALR1PIK3CAHPGDMAPT | |
| SCHEMBL3451143 | 0.81 | PIK3CA (0.46) | PIK3CAHPGDMAPTMAPK1IDH2 | |
| SCHEMBL4361997 | 0.80 | GALR2 (0.48) | GALR2GALR1ABL1KCNH2MCHR1 | |
| SCHEMBL3451034 | 0.79 | PIK3CA (0.51) | GALR2GALR1PIK3CAHPGDMAPT | |
| SCHEMBL3451519 | 0.79 | GALR1 (0.63) | GALR2GALR1PIK3CAHPGDKDM4E | |
| SCHEMBL10143797 | 0.78 | GALR2 (0.83) | GALR2GALR1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796673-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| WO-2006034473-A2 | NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | UMPS, DPYD, TYMS | GALR2 2962/4885GALR1 3000/4885PIK3CA 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.